Plain English Summary
Background and study aims
Patent ductus arteriosus (PDA) occurs when a blood vessel in the heart does not close after birth. For most babies, this vessel closes in the first few days after birth. However, when babies are born early the blood vessel can remain open as it is unable to close on its own. This can cause the baby to have to work harder to breathe and prevent the baby from gaining weight. A PDA can be closed in a preterm baby over the first 48 hours by being given ibuprofen (an anti-inflammatory (swelling) medication) through a needle in a vein. Studies have shown this to be safe way to close the PDA and prevent babies from requiring surgery. In some countries, the medication is not available through a needle in the vein and therefore studies need to be done to see if medication being given through the mouth is safe and effective. Using paracetamol (a commonly used pain medication) to close PDA has been suggested as an alternative. This study aims to compare two different types of medication (ibuprofen and paracetamol) that are given to babies by mouth to see how well they work at closing the PDA.
Who can participate?
Premature infants and newborns that weigh less than 1500 grams
What does the study involve?
Participants are allocated to one of two groups. Those in the first group are given a syrup form of paracetamol by mouth every six hours for three days. Those in the second group are given a syrup form of ibuprofen once daily for three days. Participants are followed up with an echocardiogram (a scan that uses sound waves to create a picture of the heart) after 24 hours to see if the PDA has closed. If the PDA has not closed yet, participants will receive a second course of the same medicine. If the PDA has not closed after the second course of medicine, they are given the other medicine.
What are the possible benefits and risks of participating?
Participants will benefit from having the PDA closed. There are no risks to participating.
Where is the study run from?
University of Jordan Hospital (Jordan)
When is the study starting and how long is it expected to run for?
June 2014 to February 2017
Who is funding the study?
University of Jordan (Jordan)
Who is the main contact?
Dr Manar Al-lawama
Trial website
Contact information
Type
Scientific
Primary contact
Dr Manar Al-lawama
ORCID ID
http://orcid.org/0000-0001-9313-112X
Contact details
Queen Rania Street
Amman
11943
Jordan
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
01
Study information
Scientific title
Oral paracetamol versus oral ibuprofen for the treatment of patent ductus arteriosus in preterm infants: A randomized trial
Acronym
Study hypothesis
Oral ibuprofen is better than oral paracetamol in treating patent ductus arteriosus in preterm infants.
Ethics approval
Jordan University Hospital IRB Committee, 09/11/2014, ref: 108/2014/IRB J
Study design
Single centre randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised parallel trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Patent ductus arteriosus (PDA)
Intervention
Participants are randomly allocated to receiving either oral paracetamol or oral ibuprofen. Randomisation is done through a computer generated numbers placed in opaque envelopes with sequential numbers.
Group 1 (oral paracetamol): Participants receive 10 mg/kg/dose of paracetamol orally (as a syrup) followed by 1-2 cc 0/9% saline every six hours for three days.
Group 2 (oral ibuprofen group): Participants receive 10mg/kg/dose of ibuprofen orally (as a syrup) followed by 1-2 cc 0.9% saline once daily for three days.
An echocardiogram is done within 24 hours of last treatment dose to assess the PDA. If the treatment fails, another course of the same assigned drug is given. If the treatment fails after the second course of the same drug, the patient will receive the drug from the other group. Participants are followed up if there are respiratory distress symptoms.
Intervention type
Drug
Phase
Not Specified
Drug names
1. Paracetamol
2. Ibuprofen
Primary outcome measures
1. Closure of PDA is measured by an echocadiograph within 24 hours post treatment
2. Mortality is assessed through daily follow up of the patients and their medical records.
Secondary outcome measures
1. Respiratory distress syndrome (RDS) is measured using physical examination for clinical signs of respiratory distress and chest X-ray finding at baseline
2. Bronchopulmonary dysplasia (BPD) is measured using clinical examination of the patient for the need of respiratory support or supplemented oxygen at 36 weeks post conceptional age
3. Mechanical ventilation (MV) is measured using clinical examination and reviewing patient record any time during hospital stay until discharge
4. Necrotizing enterocolitis (NEC) is measured using abdominal X-ray for the presence of pneumatosis intistinalis any time during hospital stay
5. Retinopathy of prematurity (ROP) is measured using binocular indirect ophthalmoscopy exam at 32 weeks post conceptional age for premature infants born < 28 weeks gestation or at 4 weeks chronological age for premature infants born > 28 weeks gestation
6. Intraventricular hemorrhage (IVH) is measured using trans-fontanel cranial ultrasound at 7 days of age
7. Periventricular leukomalacia (PVL) is measured using trans-fontanel cranial ultrasound at one month of age
Overall trial start date
01/06/2014
Overall trial end date
18/02/2017
Reason abandoned
Eligibility
Participant inclusion criteria
1. Premature infants born 32 weeks gestation or earlier
2. Newborns with birth weight 1500 g or under
Participant type
Patient
Age group
Neonate
Gender
Both
Target number of participants
10
Participant exclusion criteria
1. Ductal dependent congenital heart diseases
2. Major congenital malformation
3. Grade 3-4 intraventricular hemorrhage
4. Renal impairment defined as Creatinine > 1.5 mg/dl
5. Pulmonary hemorrhage
6. Thrombocytopenia < 60.000 /mm 3
7. Elevated Alanine transaminase (ALT)
Recruitment start date
01/03/2015
Recruitment end date
31/10/2016
Locations
Countries of recruitment
Jordan
Trial participating centre
Jordan University Hospital
Queen Rania Street
Amman
11943
Jordan
Sponsor information
Organisation
University of Jordan
Sponsor details
Queen Rania Street
Amman
11942
Jordan
Sponsor type
University/education
Website
Funders
Funder type
University/education
Funder name
University of Jordan
Alternative name(s)
UJ
Funding Body Type
government organisation
Funding Body Subtype
government non-federal
Location
Jordan
Results and Publications
Publication and dissemination plan
Planned publication in a high-impact peer reviewed journal by April 2017.
IPD sharing plan:
The current data sharing plans for the current study are unknown and will be made available at a later date.
Intention to publish date
30/04/2017
Participant level data
Other
Results - basic reporting
Publication summary